The therapeutic potential of ivermectin for COVID-19: a systematic review of mechanisms and evidence
Kalfas et al.,
The therapeutic potential of ivermectin for COVID-19: a systematic review of mechanisms and evidence,
medRxiv, doi:10.1101/2020.11.30.20236570 (Preprint) (meta analysis)
Review of ivermectin mechanisms and 8 trials, showing positive mortality benefit, reduced time to clinical recovery, reduced incidence of disease progression, and decreased duration of hospital admission in patients across all stages of clinical severity.
Currently there are
95 ivermectin studies and meta analysis shows:
Kalfas et al., 4 Dec 2020, preprint, 4 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.11.30.20236570; this version posted December 4, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19:
A SYSTEMATIC REVIEW OF MECHANISMS AND EVIDENCE
Stefanie Kalfas, MD1
Kumar Visvanathan, MBBS FRACP PhD2,3
Kim Chan, DSc PhD4
John Drago, MBBS FRACP PhD1,5*
1
Florey Institute of Neuroscience and Mental Health, University of Melbourne, VIC, Australia
Department of infectious Diseases, St. Vincent’s Hospital, Melbourne, VIC, Australia
3
Department of Medicine, Dentistry and Health Sciences, University of Melbourne, VIC,
Australia
4
Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, NSW,
Australia
5
Department of Neurology, St. Vincent’s Hospital, Melbourne, VIC , Australia
2
*corresponding author: john.drago@florey.edu.au
Word count (excluding abstract): 3,676
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.11.30.20236570; this version posted December 4, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
ABSTRACT
Introduction: Ivermectin is a commonly used antihelminthic agent with over 35 years of
established safety data in humans. Recent data demonstrates antiviral activity in vitro
against SARS-CoV-2, in addition to a range of viruses. In vitro and animal models also provide
evidence of immunomodulatory action. These additional modes of action are supported by
in silico modelling, which propose a number of viral and host targets that would mediate
these effects.
Objectives: The aim of this study is to systematically review the published and preprint
clinical literature and study results that assessed the potential role of ivermectin as a COVID19 therapeutic and prophylactic agent.
Methods: We conducted a comprehensive review of PubMed, medRxiv, ClinicalTrials.gov,
Global Coronavirus COVID-19 Clinical Trial Tracker, World Health Organization International
Clinical Trials Registry Platform, EU Clinical Trials Register, ANZ clinical trials registry, and
references from relevant articles.
Results: Search keywords- “COVID-19 (and synonyms) AND ivermectin”- generated 86
articles on PubMed, 48 on medRvix and 37 on clinicaltrials.gov at the time of writing. Twelve
of these were listed as completed clinical trials and of these, 8 were included as investigators
had released results. Positive mortality benefit, reduced time to clinical recovery, reduced
incidence of disease progression and decreased duration of hospital admission were
reported in patients across all stages of clinical severity.
Limitations: Due to the time-critical nature of the COVID-19 pandemic our review included
preprint data, which must be interpreted with caution while it awaits peer review.
medRxiv..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit